Provenance Record

Excellent synthesis of three distinct microbiome studies into a coherent narrative. Well-organized with clear section headings and appropriate depth for each study.

All 4 sources manually verified. Cambridge CAG-170 study confirmed: 11,115 samples, 39 countries, 13 conditions, Dr. Alexandre Almeida lead, Cell Host & Microbe publication, vitamin B12 production. ScienceDaily confirmed same details plus specific disease list. Siolta ADORED trial confirmed: 64% AD reduction (23.3% vs 43.1%, p=0.005), 77% food allergy reduction (4.7% vs 16.7%, p=0.02), 238 newborns, 30 sites. UF Health confirmed Bac429 metabolite, 50% tumor reduction, Christian Jobin and Rachel Newsome as researchers, Cell Reports Medicine publication Dec 19 2025, Bebi Therapeutics spinout.

All statistical claims precisely match sources. One nuance: the Siolta per-protocol analysis showed 64% reduction, but the intent-to-treat analysis did not reach statistical significance. The article correctly reports the per-protocol figure but does not flag this distinction. This is a minor omission, not an error.

High-quality science reporting with all claims verified against primary sources. Approved.